Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have cervical cancer (of epithelial origin) that has been confirmed by a scan (CT or MRI) and has come back or not gone away after at least one prior chemotherapy treatment.
• You have saved tumor tissue samples (from a previous biopsy or surgery) available for testing.
• Your cancer can be measured on a scan, with at least one clearly identifiable area of disease to track during the study.
• Your cancer originally came from any stage (Stage I through IV) and has now returned or spread.
• Your blood counts are at an acceptable level — enough white blood cells, platelets, and infection-fighting cells (confirm with trial site).
• Your kidneys are working well enough, based on a blood test (confirm with trial site).
• Your liver is working well enough, based on blood tests (confirm with trial site).
• You are physically well enough to carry out everyday activities with little or no difficulty (known as ECOG performance status 0 or 1 — confirm with trial site).
• You have signed a consent form agreeing to take part in the study.
• It has been at least 2 weeks since your last cancer treatment (such as chemotherapy, radiation, immunotherapy, or surgery).
• It has been at least 2 weeks since taking high-dose steroid medications (low doses may still be allowed — confirm with trial site).
• Any side effects from previous treatments have mostly cleared up (to a mild level or better), with some exceptions for mild nerve-related side effects or hair loss.
• You have had no more than 2 prior chemotherapy regimens for your cervical cancer.
• If you received immunotherapy before, at least 4 weeks have passed since your last dose.
• If you could become pregnant, you have had a negative pregnancy test within 7 days of joining and are using effective contraception during the study and for 12 weeks after treatment ends.
• You are at least 18 years old.

Who may not be able to join:

• You are pregnant or breastfeeding.
• You have had a serious allergic reaction to the study drug or its ingredients.
• You are taking certain medications that interfere with how the study drug is processed in your body (such as UGT1A1 inhibitors — confirm with trial site).
• You have other medical or mental health conditions that the study doctor feels could affect your safety or the study results.
• You have had another type of invasive cancer in the past 5 years (exceptions may be made for certain skin cancers or very early cervical changes — confirm with trial site).
• You have had a significant heart problem in the last 6 months, such as uncontrolled high blood pressure, unstable chest pain, serious heart failure, or a significant irregular heartbeat.
• You have a serious ongoing lung condition, such as severe COPD or another chronic breathing illness that was active in the last 6 months.
• You have any unstable health problem that is currently being treated, such as a recent stroke, blood clot in the lungs, serious infection requiring IV antibiotics, or significant kidney or liver problems.
• You have active cancer that has spread to the brain or the lining around the brain, unless previously treated brain spread has been stable for at least 4 weeks and all symptoms have returned to normal (confirm with trial site).
• You have an uncontrolled seizure disorder or active neurological disease.
• You have HIV with a detectable level of virus in your blood, or are taking medications that may interfere with the study drug.
• You have active Hepatitis B or C, or a history of either with detectable virus levels.
• You have a known bleeding disorder.
• You have a condition called Gilbert's disease (a liver-related condition affecting how the body processes certain substances).
• You have a single tumor mass larger than 7 cm (though exceptions may be discussed with the lead study doctor).
• You are currently experiencing moderate or severe loss of appetite, nausea, vomiting, or signs of a bowel blockage.
• You have had a bowel blockage within the last 6 months.
• You have previously had a severe allergic reaction to a drug called irinotecan, or had serious side effects from it.
• You have previously received a type of chemotherapy called a topoisomerase I inhibitor (confirm with trial site).

**Important: Always verify eligibility with the trial site directly before applying